Multisystem Benefits of GLP-1 Microdosing: A Narrative Review.

Glucagon-like peptide-1 (GLP-1) is an endocrine hormone that plays a role in lowering blood glucose levels and promoting weight loss. GLP-1 receptor agonists (GLP-1 RAs) are synthetic peptides that mimic the activity of GLP-1, and the recent development of GLP-1 RA medications has been a major historical advancement in the treatment of diabetes and obesity. Despite the rapid development of GLP-1 RA medications, there is a very high demand for the limited supply of these drugs, resulting in high medication costs and significant care gaps among prescribed patients. This shortage has forced providers to be more strategic and creative with their treatments in order to support therapeutic continuity, which has led to an increased utilization of medication microdosing. This article aims to summarize available evidence on the effects of GLP-1 RAs and the possible benefits of long-term microdosing GLP-1 RA medications.